BNIP3抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using BNIP3 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using BNIP3 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human breast cancer tissues using BNIP3 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using BNIP3 mouse mAb with DAB staining.    

  
  

BNIP3 (BCL2/adenovirus E1B 19 kDa protein-interacting protein 3) is a pro-apoptotic mitochondrial protein belonging to the Bcl-2 family, primarily involved in regulating apoptosis, autophagy, and mitochondrial homeostasis. It contains a Bcl-2 homology 3 (BH3) domain and a transmembrane domain, enabling interaction with Bcl-2 family members and integration into mitochondrial/lysosomal membranes. BNIP3 is upregulated under hypoxic conditions via HIF-1α, linking it to cellular responses in ischemia, cancer, and neurodegeneration. In cancer, BNIP3’s role is context-dependent, acting as a tumor suppressor by promoting apoptosis or supporting tumor survival via autophagy in hypoxic microenvironments. It also contributes to mitophagy by recruiting autophagosomes to damaged mitochondria.

BNIP3 antibodies are essential tools for detecting BNIP3 expression in research applications such as Western blotting, immunohistochemistry, and immunofluorescence. These antibodies help elucidate BNIP3’s involvement in diseases, including its dysregulation in tumors, cardiomyocyte apoptosis in heart failure, and neuronal death in neurodegenerative disorders. Commercial BNIP3 antibodies are typically raised against specific epitopes (e.g., human BNIP3 N-terminal or C-terminal regions) and validated for cross-reactivity in human, mouse, or rat samples. Researchers rely on these antibodies to study BNIP3’s interaction partners, post-translational modifications, and therapeutic targeting potential in conditions like cancer and metabolic diseases.